Who are Cladribine (CLAD)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cladribine Tablets, Fludarabine (FLU), Mavenclad®, Cladribine High Dose, Cladribine Low Dose, Cladribine Pill.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cladribine-clad.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Cladribine (CLAD) — Competitive Intelligence Brief

Cladribine (CLAD) (Cladribine (CLAD)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Purine nucleoside analog. Area: Oncology.

marketed Purine nucleoside analog DNA (via deoxyadenosine analog incorporation) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Cladribine (CLAD) (Cladribine (CLAD)) — M.D. Anderson Cancer Center. Cladribine is a purine nucleoside analog that is phosphorylated intracellularly and incorporated into DNA, causing strand breaks and apoptosis in lymphoid cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Cladribine (CLAD) TARGET	Cladribine (CLAD)	M.D. Anderson Cancer Center	marketed	Purine nucleoside analog	DNA (via deoxyadenosine analog incorporation)
Cladribine Tablets	Cladribine Tablets	Keith Edwards, M.D.	marketed	Purine nucleoside analog	Ribonucleotide reductase; DNA incorporation
Fludarabine (FLU)	Fludarabine (FLU)	Nanfang Hospital, Southern Medical University	marketed	Purine nucleoside analog	Ribonucleotide reductase, DNA polymerase
Mavenclad®	Mavenclad®	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	marketed	Purine nucleoside analog; immunosuppressant	Deoxyadenosine kinase; DNA synthesis and repair pathways in lymphocytes
Cladribine High Dose	Cladribine High Dose	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	phase 3	Purine nucleoside analog	DNA (via deoxyadenosine analog incorporation)
Cladribine Low Dose	Cladribine Low Dose	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany	phase 3	Purine nucleoside analog	Ribonucleotide reductase; DNA synthesis
Cladribine Pill	Cladribine Pill	Haukeland University Hospital	phase 3	Purine nucleoside analog	Ribonucleotide reductase; DNA incorporation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Purine nucleoside analog class)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · 2 drugs in this class
Haukeland University Hospital · 1 drug in this class
Keith Edwards, M.D. · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class
Nanfang Hospital, Southern Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cladribine (CLAD) — Competitive Intelligence Brief. https://druglandscape.com/ci/cladribine-clad. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab